The degradation of Aβ25-35 by the serine protease plasmin is inhibited by aluminium

Journal of Alzheimer's Disease

Volumn 4, Issue 5, 2002, Pages 357-367

  Korchazhkina, Olga V ^a   Ashcroft, Alison E ^b   Kiss, Tamas ^c   Exley, Christopher ^a  

^a KEELE UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c UNIVERSITY OF SZEGED   (Hungary)

Author keywords

Aluminium; Alzheimer's disease; Amyloid; A catabolism; Plasmin; Urokinase plasminogen activator system

Indexed keywords

ALUMINUM; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[25-35]; AMYLOID PRECURSOR PROTEIN; PLASMIN; SERINE PROTEINASE; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN (25 36); AMYLOID BETA-PROTEIN (25-36);

ALZHEIMER DISEASE; ARTICLE; CATABOLISM; IN VITRO STUDY; ONSET AGE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; DRUG ANTAGONISM; DRUG EFFECT; FLUORESCENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; METABOLISM;

ALUMINUM; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FLUORESCENCE; HUMANS; PLASMIN; SERINE ENDOPEPTIDASES;

EID: 0036813102     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2002-4503     Document Type: Article

References (50)

1. R. Abraham, A. Myers and F. Wavrant-DeVrieze et al., Substantial linkage disequilibrium across the insulin-degrading enzyme locus but no association with late-onset Alzheimer's disease, Hum Genet 109 (2001), 646-652.
2. H. Akiyama, K. Ikeda, H. Kondo, M. Kato and P.L. McGeer, Microglia express the type-2 plasminogen-activator inhibitor in the brain of control subjects and patients with Alzheimer's disease, Neurosci Lett 164 (1993), 233-235.
3. D.F. Alonso, E.F. Farias and A.L. Famulari et al., Excessive urokinase-type plasminogen activator activity in the euglobulin fraction of patients with Alzheimer-type dementia, J Neurol Sci 139 (1996), 83-88.
4. M. Angeletti, G. Lupidi and A.M. Eleuteri et al., Effect of aluminum on the binding properties of α-chymotrypsin, J Biol Inorg Chem 2 (1997), 320-326.
5. T. Aoyagi, T. Wada and F. Kojima et al., Deficiency of fibrinolytic enzyme-activities in the serum of patients with Alzheimer-type dementia, Experientia 48 (1992), 656-659.
6. M. Asahina, Y. Yoshiyama and T. Hattori, Expression of matrix metalloproteinase-9 and urinary-type plasminogen activator in Alzheimer's disease brain, Clin Neuropathol 20 (2001), 60-63.
7. W.A. Banks, L.M. Maness, M.F. Banks and A.J. Kastin, Aluminum-sensitive degradation of amyloid β-protein(1-40) by murine and human intracellular enzymes, Neurotoxicol Teratol 18 (1996), 671-677.
8. L. Bertram, D. Blacker and K. Mullin et al., Evidence for genetic linkage of Alzheimer's disease to chromosome 10q, Science 290 (2000), 2302-2303.
9. J.A. Carson and A.J. Turner, β-amyloid catabolism: Roles for neprilysin (NEP) and other metallopeptidases? J Neurochem 81 (2002), 1-8.
10. A.M. Cataldo and R.A. Nixon, Enzymatically active lysosomal proteases are associated with amyloid deposits in Alzheimer brain, Proc Natl Acad Sci USA 87 (1990), 3861-3865.
11. M. Citron, T. Oltersdoff and C. Haass et al., Mutation of the β-amyloid precursor protein in familial Alzheimer's disease increases β-protein production, Nature 360 (1992), 672-674.
12. M. Clauberg and J.G. Joshi, Regulation of serine protease activity by aluminum - Implications for Alzheimer's disease, Proc Natl Acad Sci USA 90 (1993), 1009-1012.
13. M.H. Deininger, K. Trautmann and V. Magdolen et al., Cortical neurons of Creutzfeldt-Jakob disease patients express the urokinase-type plasminogen activator receptor, Neurosci Lett 324 (2002), 80-82.
14. V. di Noto, L. dalla Via and P. Zatta, Conformational studies of the trypsin-aluminum(III) complex in solution by Raman and Fourier transform infrared attenuated total reflectance spectroscopy, J Raman Spectrosc 30 (1999), 209-216.
15. V. Di Noto, L.D. Via and P. Zatta, Review of binding methods and detection of Al(III) binding events in trypsin and DL-DPPC liposomes by a general thermodynamic model, Coord Chem Rev (in Press).
16. E.A. Eckman, D.K. Reed and C.B. Eckman, Degradation of the Alzheimer's amyloid β peptide by endothelin-converting enzyme, J Biol Chem 276 (2001), 24540-24548.
17. C. Exley, ed., Aluminium and Alzheimer's Disease: The Science that Describes the Link, Elsevier, Amsterdam, 2001, pp. 441.
18. C. Exley, ATP-promoted amyloidosis of an amyloid β peptide, Neuroreport 8 (1997), 3411-3414.
19. C. Exley and J.D. Birchall, Biological availability of aluminum in commercial ATP, J Inorg Biochem 63 (1996), 241-252.
20. C. Exley and O.V. Korchazhkina, Plasmin cleaves Aβ 42 in vitro and prevents its aggregation into β-pleated sheet structures, Neuroreport 12 (2001), 2967-2970.
21. C. Exley and O.V. Korchazhkina, Promotion of formation of amyloid fibrils by aluminium adenosine triphosphate (A1ATP), J Inorg Biochem 84 (2001), 215-224.
22. S. Fukami, K. Watanabe and N. Iwata et al., Aβ-degrading endopeptidase, neprilysin, in mouse brain: Synaptic and axonal localization inversely correlating with Aβ pathology, Neuroscience Research 43 (2002), 39-56.
23. J.T. Gau, M.L. Steinhilb and T.C. Kao et al., Stable β-secretase activity and presynaptic cholinergic markers during progressive central nervous system amyloidogenesis in Tg2576 mice, Am J Pathol 160 (2002), 731-738.
24. G.G. Glenner and C.W. Wong, Alzheimer's disease - Initial report of the purification and characterization of a novel cerebrovascular amyloid protein, Biochem Biophys Res Commun 120 (1984), 885-890.
25. E. Hama, K. Shirotani and H. Masumoto et al., Clearance of extracellular and cell-associated amyloid β peptide through viral expression of neprilysin in primary neurons, J Biochem (Tokyo) 130 (2001), 721-726.
26. H. Hino, H. Akiyama and E. Iseki et al., Immunohistochemical localization of plasminogen activator inhibitor-1 in rat and human brain tissues, Neurosci Lett 297 (2001), 105-108.
27. J.G. Hu, A. Igarashi, M. Kamata and H. Nakagawa, Angiotensin-converting enzyme degrades Alzheimer amyloid β-peptide (Aβ); retards Aβ aggregation, deposition, fibril formation, and inhibits cytotoxicity, J Biol Chem 276 (2001), 47863-47868.
28. N. Iwata, S. Tsubuki and Y. Takaki et al., Metabolic regulation of brain Aβ by neprilysin, Science 292 (2001), 1550-1552.
29. T. Kiss and M. Hollosi, The interaction of aluminium with peptides and proteins, in: Aluminium and Alzheimer's Disease: The Science that Describes the Link, C. Exley, ed., Elsevier, Amsterdam, 2001, pp. 361-392.
30. T. Kiss, I. Sovago and R.B. Martin, Al3+ binding by adenosine 5′-phosphates - AMP, ADP, and ATP, Inorg Chem 30 (1991), 2130-2132.
31. I.V. Kurochkin and S. Goto, Alzheimers &-amyloid peptide specifically interacts with and is degraded by insulin degrading enzyme, FEBS Lett 345 (1994), 33-37.
32. D. Lauer, A. Reichenbach and G. Birkenmeier, α 2-Macroglobulin-mediated degradation of amyloid β 1-42: A mechanism to enhance amyloid β catabolism, Exp Neurol 167 (2001), 385-392.
33. M.D. Ledesma, J.S. Da Silva and K. Crassaerts et al., Brain plasmin enhances APP α-cleavage and Aβ degradation and is reduced in Alzheimer's disease brains, EMBO Rep 1 (2000), 530-535.
34. H. Levine, Thioflavine-T interaction with synthetic Alzheimer's disease β-amyloid peptides - detection of amyloid aggregation in solution, Protein Sci 2 (1993), 404-410.
35. A. Matsumoto, K. Itoh, T. Seki, K. Motozaki and S. Matsuyama, Human brain carboxypeptidase B, which cleaves β-amyloid peptides in vitro, is expressed in the endoplasmic reticulum of neurons, Eur J Neurosci 13 (2001), 1653-1657.
36. M. Oda, H. Morino and H. Maruyama et al., Dinucleotide repeat polymorphisms in the neprilysin gene are not associated with sporadic Alzheimer's disease, Neurosci Lett 320 (2002), 105-107.
37. A. Perez, L. Morelli, J.C. Cresto and E.M. Castano, Degradation of soluble amyloid β-peptides 1-40, 1-42, and the Dutch variant 1-40Q by insulin degrading enzyme from Alzheimer disease and control brains, Neurochem Res 25 (2000), 247-255.
38. S.E. Poduslo, X. Yin and J. Hargis et al., A familial case of Alzheimer's disease without tau pathology may be linked with chromosome 3 markers, Hum Genet 105 (1999), 32-37.
39. D.J. Selkoe, Clearing the brain's amyloid cobwebs, Neuron 32 (2001), 177-180.
40. N. Sodeyama, H. Mizusawa and M. Yamada et al., Lack of association of neprilysin polymorphism with Alzheimer's disease and Alzheimer's disease-type neuropathological changes, J Neurol Neurosurg Psychiatry, 71 (2001), 817-818.
41. S. Sudoh, M.P. Frosch and B.A. Wolf, Differential effects of proteases involved in intracellular degradation of amyloid β-protein between detergent-soluble and -insoluble pools in CHO-695 cells, Biochemistry 41 (2002), 1091-1099.
42. Y. Takaki, N. Iwata and S. Tsubuki et al., Biochemical identification of the neutral endopeptidase family member responsible for the catabolism of amyloid β peptide in the brain, J Biochem (Tokyo) 128 (2000), 897-902.
43. R.E. Tanzi and L. Bertram, New frontiers in Alzheimer's disease genetics, Neuron 32 (2001), 181-184.
44. H.M. Tucker, M. Kihiko and J.N. Caldwell et al., The plasmin system is induced by and degrades amyloid-β aggregates, J Neurosci 20 (2000), 3937-3946.
45. W.E. Van Nostrand and M. Porter, Plasmin cleavage of the amyloid β-protein: Alteration of secondary structure and stimulation of tissue plasminogen activator activity, Biochemistry 38 (1999), 11570-11576.
46. K. Vekrellis, Z. Ye and W.Q. Qiu et al., Neurons regulate extracellular levels of amyloid β-protein via proteolysis by insulin-degrading enzyme, J Neurosci 20 (2000), 1657-1665.
47. D.G. Walker, L.F. Lue and T.G. Beach, Increased expression of the urokinase plasminogen-activator receptor in amyloid β peptide-treated human brain microglia and in AD brains, Brain Res 926 (2002), 69-79.
48. D.M. Walsh, I. Klyubin and J.V. Fadeeva et al., Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo, Nature 416 (2002), 535-539.
49. K. Yasojima, H. Akiyama, E.G. McGeer and P.L. McGeer, Reduced neprilysin in high plaque areas of Alzheimer brain: A possible relationship to deficient degradation of β-amyloid peptide, Neurosci Lett 297 (2001), 97-100.
50. P. Zatta, C. Bordin and M. Favarato, The inhibition of trypsin and α-chymotrypsin proteolytic activity by aluminum(III), Arch Biochem Biophys 303 (1993), 407-411.